Why do rare disease patients still face barriers to accessing medicines across Europe?
Accessing a prescribed therapy is often assumed to be straightforward after approval. However, across Europe’s diverse healthcare systems, many patients living with rare diseases and rare cancers continue to encounter practical, logistical, and informational obstacles that complicate treatment access and continuity.
This whitepaper explores insights from a multi-country European patient survey, highlighting the hidden burden of medicine collection, the variability of patient experience and the opportunities to reduce friction through more integrated, patient-centred delivery models.
Download to discover:
- The real-world burden of travelling to collect life-saving medicines
- How time, cost and system design shape the patient experience
- The awareness gap surrounding home delivery options
- Why reliable medicine access is a core component of care
- Practical considerations for designing patient-centred delivery models
Download your free copy and understand how care pathways can better support rare disease patients.
About Sciensus
Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.
Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.